XOMA Royalty (NASDAQ:XOMA) Downgraded by Zacks Research to “Strong Sell”

Zacks Research lowered shares of XOMA Royalty (NASDAQ:XOMA) from a hold rating to a strong sell rating in a report published on Tuesday,Zacks.com reports.

Several other equities research analysts have also issued reports on XOMA. HC Wainwright dropped their price objective on shares of XOMA Royalty from $104.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. TD Cowen raised shares of XOMA Royalty to a “hold” rating in a research report on Friday, February 13th. Leerink Partners reiterated an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Benchmark reissued a “buy” rating on shares of XOMA Royalty in a research report on Friday, December 12th. Finally, Wall Street Zen cut XOMA Royalty from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Three analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $61.60.

XOMA Royalty Stock Performance

XOMA Royalty stock opened at $26.96 on Tuesday. The company has a debt-to-equity ratio of 1.07, a current ratio of 3.91 and a quick ratio of 3.91. XOMA Royalty has a 12 month low of $18.35 and a 12 month high of $39.92. The company has a market cap of $333.76 million, a price-to-earnings ratio of 36.43 and a beta of 0.86. The stock’s 50-day moving average is $26.15 and its 200-day moving average is $30.72.

Institutional Investors Weigh In On XOMA Royalty

A number of large investors have recently added to or reduced their stakes in the company. Stonepine Capital Management LLC lifted its holdings in XOMA Royalty by 17.2% in the 2nd quarter. Stonepine Capital Management LLC now owns 152,143 shares of the biotechnology company’s stock worth $3,834,000 after buying an additional 22,330 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA Royalty during the second quarter valued at about $370,000. Panagora Asset Management Inc. purchased a new stake in shares of XOMA Royalty during the second quarter worth about $463,000. Squarepoint Ops LLC purchased a new stake in shares of XOMA Royalty during the fourth quarter worth about $237,000. Finally, BNP Paribas Financial Markets lifted its stake in shares of XOMA Royalty by 266.6% in the third quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 2,346 shares in the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.